Assessing the efficacy and safety of nasal NeuroEpo management in Patients disease with Parkinson stage II-III - mAkEUP

Trial Profile

Assessing the efficacy and safety of nasal NeuroEpo management in Patients disease with Parkinson stage II-III - mAkEUP

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Recombinant erythropoietin (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms mAkEUP
  • Most Recent Events

    • 07 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top